Clinical Trial Detail

NCT ID NCT03871348
Title A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Sanofi
Indications

melanoma

Advanced Solid Tumor

lymphoma

skin squamous cell carcinoma

head and neck squamous cell carcinoma

Therapies

SAR441000

Cemiplimab + SAR441000

Age Groups: adult senior

No variant requirements are available.